Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Elu... (These factors in some caseshave affected...)

Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent

Date:10/10/2008

These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Press Contact:

Paul Donovan

Media Relations

Boston Scientific Corporation

508-650-8541 (office)

508-667-5165 (mobile)

Larry Neumann

Investor Relations

Boston Scientific Corporation

508-650-8696 (office)

3

GOOD

Page: 1 2 3
Related biology technology :

1. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
2. Video: Moms Raise Red Flag About the Dangers of Widely Undiagnosed Bleeding Disorder
3. Video: Fortune 1000 Executives: New President Must Fix Education Gap
4. Video: Keppra XR(TM) Approved in the U.S.
5. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
6. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
7. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
8. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
9. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
10. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
11. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges

Post Your Comments:

Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Elu...(These factors in some caseshave affected...)